Case Report: Patient-derived organoids guiding dabrafenib–trametinib therapy in BRAFV600E-mutant metastatic gastric cancer
Frontiers in Oncology · 20.05.2026 · 16
DOI: 10.3389/fonc.2026.1813652 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 20.05.2026. Verfasst von Caifeng Gong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and …. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
BRAF V600E mutations occur in approximately 0.4% of gastric cancer (GC) cases and are associated with aggressive disease and limited therapeutic options. Cytotoxic chemotherapy remains the standard first-line treatment for this rare molecular subtype, while evidence-based targeted strategies are lacking. Patient-derived organoids (PDOs) have emerged as a functional platform for precision oncology, but their clinical utility in BRAF V600E -mutant GC remains largely unexplored. Case presentation A patient with rapidly progressive BRAF V600E -mutant metastatic GC presented with mediastinal invasion and malignant pleural effusion, posing a diagnostic challenge in distinguishing metastatic GC from a primary thoracic malignancy. Concordant histopathologic and genomic profiling across multiple tumor sites ultimately confirmed a gastric origin. Despite standard chemotherapy and immunotherapy, the disease progressed rapidly. Patient-derived organoids (PDOs) were established from malignant pleural effusion and used for functional drug sensitivity testing, which demonstrated marked sensitivity to dual BRAF-MEK inhibition. Based on these findings, the patient was treated with dabrafenib plus trametinib, resulting in prompt symptomatic improvement and radiologic regression of pleural effusion and ascites, consistent with PDO-predicted response.
Conclusion
This case suggests that dual BRAF-MEK inhibition may represent a feasible precision treatment option for patients with BRAF V600E -mutant GC lacking established targeted therapies. Moreover, it highlights the potential role of PDOs as a functional decision-support platform for guiding individualized treatment selection in rare, genomically defined GC subtypes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Darkjade Sciences, Inc., Beijing, China.
Zitieren
APA
Gong, C., Yang, Y., Yan, Q., Zhao, W., Zhang, M., Zhang, W., You, S., Yin, R., Huang, Y., Zhao, Y., & Zhou, A. (2026). Case Report: Patient-derived organoids guiding dabrafenib–trametinib therapy in BRAFV600E-mutant metastatic gastric cancer. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1813652
Vancouver
Gong C, Yang Y, Yan Q, Zhao W, Zhang M, Zhang W, et al. Case Report: Patient-derived organoids guiding dabrafenib–trametinib therapy in BRAFV600E-mutant metastatic gastric cancer. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1813652
BibTeX
@article{Gong2026,
author = {Gong, Caifeng and Yang, Yang and Yan, Qi and Zhao, Weiting and Zhang, Minghao and Zhang, Wen and You, Shuhui and Yin, Ruihong and Huang, Yang and Zhao, Yunshan and Zhou, Aiping},
title = {Case Report: Patient-derived organoids guiding dabrafenib–trametinib therapy in BRAFV600E-mutant metastatic gastric cancer},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1813652}
}
EUVIMED